CN114269301A - 用于治疗老视的组合物和方法 - Google Patents

用于治疗老视的组合物和方法 Download PDF

Info

Publication number
CN114269301A
CN114269301A CN202080059430.4A CN202080059430A CN114269301A CN 114269301 A CN114269301 A CN 114269301A CN 202080059430 A CN202080059430 A CN 202080059430A CN 114269301 A CN114269301 A CN 114269301A
Authority
CN
China
Prior art keywords
topical ophthalmic
ophthalmic composition
present
concentration
carbachol
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202080059430.4A
Other languages
English (en)
Chinese (zh)
Inventor
M·R·罗宾逊
M·蒂巴斯
A·戈雷
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Allergan Inc
Original Assignee
Allergan Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Allergan Inc filed Critical Allergan Inc
Publication of CN114269301A publication Critical patent/CN114269301A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/27—Esters, e.g. nitroglycerine, selenocyanates of carbamic or thiocarbamic acids, meprobamate, carbachol, neostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/683—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/10—Ophthalmic agents for accommodation disorders, e.g. myopia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/186—Quaternary ammonium compounds, e.g. benzalkonium chloride or cetrimide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Ophthalmology & Optometry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Emergency Medicine (AREA)
  • Inorganic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CN202080059430.4A 2019-07-26 2020-07-24 用于治疗老视的组合物和方法 Pending CN114269301A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962879296P 2019-07-26 2019-07-26
US62/879,296 2019-07-26
PCT/US2020/043534 WO2021021646A1 (en) 2019-07-26 2020-07-24 Compositions and methods for treatment of presbyopia

Publications (1)

Publication Number Publication Date
CN114269301A true CN114269301A (zh) 2022-04-01

Family

ID=74229810

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202080059430.4A Pending CN114269301A (zh) 2019-07-26 2020-07-24 用于治疗老视的组合物和方法

Country Status (9)

Country Link
US (1) US20220273605A1 (https=)
EP (1) EP4003246A4 (https=)
JP (1) JP2022541854A (https=)
KR (1) KR20220041151A (https=)
CN (1) CN114269301A (https=)
AU (1) AU2020323475A1 (https=)
CA (1) CA3147107A1 (https=)
MX (1) MX2022001069A (https=)
WO (1) WO2021021646A1 (https=)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2021236671A1 (en) 2020-05-18 2021-11-25 Vyluma Inc. Low-dose carbachol compositions and methods for treatment of night vision disturbance
WO2022249069A1 (en) * 2021-05-26 2022-12-01 Vyluma Inc. Low-dose carbachol ophthalmic compositions with cumulative effect
TW202333662A (zh) 2021-11-10 2023-09-01 美商偉視醫療股份有限公司 增強抗老花眼效果之卡巴可(carbachol)調配物
TW202333700A (zh) * 2021-12-16 2023-09-01 美商倫茨治療公司 用於治療眼病之組成物及方法

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4136177A (en) * 1977-01-31 1979-01-23 American Home Products Corp. Xanthan gum therapeutic compositions
US20080131484A1 (en) * 2006-12-01 2008-06-05 Allergan, Inc. Intraocular drug delivery systems
WO2010125416A1 (en) * 2009-04-27 2010-11-04 Raouf Rekik Drug delivery to the anterior and posterior segments of the eye
US20100298335A1 (en) * 2009-05-22 2010-11-25 Kaufman Herbert E Preparations and Methods for Ameliorating or Reducing Presbyopia
US20150065511A1 (en) * 2013-08-28 2015-03-05 Presbyopia Therapies, LLC Compositions and Methods for the Treatment of Presbyopia

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8299079B2 (en) * 2009-05-22 2012-10-30 Kaufman Herbert E Preparations and methods for ameliorating or reducing presbyopia

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4136177A (en) * 1977-01-31 1979-01-23 American Home Products Corp. Xanthan gum therapeutic compositions
US20080131484A1 (en) * 2006-12-01 2008-06-05 Allergan, Inc. Intraocular drug delivery systems
WO2010125416A1 (en) * 2009-04-27 2010-11-04 Raouf Rekik Drug delivery to the anterior and posterior segments of the eye
US20100298335A1 (en) * 2009-05-22 2010-11-25 Kaufman Herbert E Preparations and Methods for Ameliorating or Reducing Presbyopia
US20150065511A1 (en) * 2013-08-28 2015-03-05 Presbyopia Therapies, LLC Compositions and Methods for the Treatment of Presbyopia

Also Published As

Publication number Publication date
CA3147107A1 (en) 2021-02-04
US20220273605A1 (en) 2022-09-01
KR20220041151A (ko) 2022-03-31
WO2021021646A1 (en) 2021-02-04
EP4003246A4 (en) 2023-08-16
AU2020323475A1 (en) 2022-03-03
JP2022541854A (ja) 2022-09-27
EP4003246A1 (en) 2022-06-01
MX2022001069A (es) 2022-02-14

Similar Documents

Publication Publication Date Title
US20250049761A1 (en) Compositions and methods for treating presbyopia, mild hyperopia, and irregular astigmatism
WO2020219707A1 (en) Compositions and methods for treatment of ocular conditions
CN114269301A (zh) 用于治疗老视的组合物和方法
US20220273557A1 (en) Compositions and methods for treatment of presbyopia
HK40072203A (en) Compositions and methods for treatment of presbyopia
HK40011588A (en) Compositions and methods for treating presbyopia, mild hyperopia, and irregular astigmatism
NZ623037B2 (en) Compositions and methods for treating presbyopia, mild hyperopia, and irregular astigmatism
HK1198426B (en) Compositions and methods for treating presbyopia, mild hyperopia, and irregular astigmatism

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 40072203

Country of ref document: HK

WD01 Invention patent application deemed withdrawn after publication
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20220401